Klotho deficiency causes vascular calcification in chronic kidney disease.

By M. Hu, Mingjun Shi, Jianning Zhang, Henry Quiñones, Carolyn Griffith, M. Kuro-o, O. Moe. Journal of the American Society of Nephrology, 2011

856 citations recorded by the source corpus.

Subfields: Genetics, Nephrology, Nutrition and Dietetics

View Paper: https://www.semanticscholar.org/paper/1d1c67f7fcb0bde49764a56c24a22af010fab8f9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. J. Lo
2. Chi-yuan Hsu

In Nephrology

1. Harold I. Feldman
2. J. Kusek

In Nutrition and Dietetics

1. P. Norman
2. J. Powell

Citations in the corpus

• Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients with Chronic Kidney Disease (2011, background): “Finally, the lack of a validated assay in chronic kidney disease precluded us from measuring circulating levels of the soluble form of klotho, the FGF-23 coreceptor that is expressed in the kidneys and parathyroid glands and that demonstrates antiaging and vascular-protective effects.(29,30) Future ”
• Vitamin D and cardiovascular disease. (2014, background): “Two recent studies, one in mice and one in humans, have indicated strongly that Klotho is protective against vascular calcification by preventing the conversion of VSMC to an osteotypic phenotype.(132,133) Ectopic calcification seen in mice models with loss of function for either Klotho or fibroblas”